(Q46530192)

English

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy

scientific article published in June 2008

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

title

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

author name string

J R Berger

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

publication date

1 June 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

published in

Multiple Sclerosis Journal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

volume

14

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

page(s)

708-710

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

cites work

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1352458507087135

retrieved

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1352458507087135

retrieved

21 January 2018

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F1352458507087135

retrieved

21 January 2018

Identifiers

DOI

10.1177/1352458507087135

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

PubMed publication ID

18566035

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18566035

retrieved

22 December 2017

reference URL

http://europepmc.org/abstract/MED/18566035

(Q46530192)

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)